Schizophreniform Disorders: Clinical Trials

5 trials for Schizophreniform Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 5
Phase 21Completed 1

Follow Schizophreniform Disorders: new trials by email Literature Review of Schizophreniform Disorders trials Research Report on Schizophreniform Disorders

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
BXCL501, Matching Placebo - Agitation,Psychomotor, Bipolar I Disorder
Phase 3CompletedBioXcel Therapeutics Inc4522022-11-212026-08-07
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film - Agitation, Schizophrenia
Phase 3CompletedBioXcel Therapeutics Inc3802020-01-242026-08-11
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
ALKS 3831, Olanzapine - Schizophrenia, Schizophreniform Disorders
Phase 3CompletedAlkermes, Inc.4262017-06-082023-01-19
Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
Estradiol, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 3CompletedTangent Data2092015-12-042020-05-22
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C, Etyl EPA (placebo) - Schizophrenia, Schizophreniform Disorders
Phase 2 / Phase 3CompletedUniversity Hospital, Aker992001-09-012011-01-04

Narrower conditions

Psychotic Disorders (5)  ·  Schizophrenia (5)  ·  Psychomotor Agitation (2)  ·  Bipolar Disorder (1)  ·  Delusions (1)  ·  Hallucinations (1)  ·  Hypertriglyceridemia (1)

Broader conditions

Mental Disorders (5)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (5)  ·  Behavior (3)  ·  Behavioral Symptoms (3)  ·  Nervous System Diseases (3)  ·  Neurobehavioral Manifestations (3)  ·  Neurologic Manifestations (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Signs and Symptoms (3)  ·  Aberrant Motor Behavior in Dementia (2)  ·  Dyskinesias (2)  ·  Psychomotor Disorders (2)  ·  Bipolar and Related Disorders (1)  ·  Dyslipidemias (1)  ·  Hyperlipidemias (1)

Interventions

Dexmedetomidine (2)  ·  Estradiol (1)  ·  Olanzapine (1)  ·  eicosapentaenoic acid ethyl ester (1)

Sponsors

BioXcel Therapeutics Inc (2)  ·  Alkermes, Inc. (1)  ·  Tangent Data (1)  ·  University Hospital, Aker (1)

Countries

United States (3)  ·  Austria (1)  ·  Germany (1)  ·  Ireland (1)  ·  Israel (1)  ·  Italy (1)  ·  Moldova (1)  ·  Norway (1)  ·  Poland (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Ukraine (1)  ·  United Kingdom (1)

Top investigators

BioXcel MM (1)  ·  BioXcel MM, MD (1)  ·  Paull G Radu, M.D. (1)

Results publications

PMID 31365044, PMID 36002761, PMID 36198061, PMID 36946605